IndraLab
Statements
reach
"To further investigate the role of ERK1/2 and p38 signaling in OTUD5-mediated promotion of HNF4ɑ or HNF1ɑ, we treated the OTUD5-sh HepG2.2.15 cells with ERK1/2-specific pharmacological inhibitor (PD98059), JNK-specific pharmacological inhibitor (SP600125) and p38-specific pharmacological inhibitor (SB203580), and then tested the effect of OTUD5 on the protein level of HNF1α and HNF4α."